Navigation Links
Elusys Releases New Data On Anthrax Anti-Toxin Administered Via Intramuscular Injection From Three Recent Animal Studies
Date:7/31/2013

loped for treatment of inhalational anthrax. ETI-204 is formulated as a solution and is being evaluated for intravenous (IV) and/or intramuscular (IM) administration.

ETI-204 efficacy and safety is being studied in animal models of inhalational anthrax and safety studies are being conducted with human volunteers. Three studies assessing pharmacokinetics and safety of intravenous (IV) administration of ETI-204 in humans have been completed. The more common adverse events related to ETI-204 administration across the three studies included upper respiratory tract infection, nausea, headache, nasal congestion and erythema. ETI-204 was granted Fast Track status and Orphan Drug Designation by the FDA. 

This program is supported with federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), the Department of Health and Human Services (HHS) under Contract Nos. HHSO100201000026C and HHS0100201100034C.

About Elusys Therapeutics, Inc.
Elusys Therapeutics, a private company based in Pine Brook, NJ, is focused on the development of antibody therapeutics for the treatment of infectious disease. Elusys has been engaged in the development of ETI-204, an anthrax biowarfare countermeasures since 2000. The company has received multiple grants and contracts totaling over $200 million to support the development of ETI-204 to protect people in the event of an anthrax attack. Today, ETI-204 has advanced to the final stages of development, and is closer to achieving the company's goals of receiving FDA licensure and becoming part of the Strategic National Stockpile. For more information, please visit www.elusys.com.

SAFE HARBOR STATEMENT

This announcement includes statements that are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. This r
'/>"/>

SOURCE Elusys Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Elusys Awarded Additional $50.2 Million Under An Exisiting U.S. Government Contract To Support Final Stages Of Development Of ETI-204, For Treatment Of Inhalational Anthrax
2. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
3. HCCS Releases ICD-10 Countdown Clock With Integrated CMS Twitter Tweets
4. eCareSoft Releases eCS Cirrus™
5. AtheroNova Releases 2011 Financial Results
6. Atlanta LASIK Surgeon Dr. Ashraf Releases YouTube Videos Featuring Patient Testimonials and Discussion of Common Eye Treatments
7. ILVO-T&V Belgium Releases Validation Report of the Charm Sciences Beta-lactam and Tetracycline 2-minute Test for Raw Commingled Milk
8. ISPE Releases New Guidance for Designing and Constructing Packaging, Labeling and Warehousing Facilities
9. Happtique Releases Draft App Certification Program Standards For Public Comment
10. ClearCanvas Releases New Workstation Products Designed to Assist With Image Sharing
11. OneMedPlace Releases Update to Research Report on Amarantus Biosciences Focused on New Positive Ischemic Heart Disease Efficacy Data for MANF in Animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... balances – 4 steps – One Recommendation: the web-based ... narrows down the mass of product choices to a ... , First, select the working environment, then enter the ... define the accuracy – it’s really that simple. Specifying ... to models that fit best with the customer’s industry ...
(Date:7/24/2014)... 2014 Draper University, a top ... to announce that for 6 weeks this summer, ... converge on the Draper University campus in the ... program focused on entrepreneurship, building real-world skills, and ... running its sixth cohort, continues to refresh its ...
(Date:7/24/2014)... 2014   Cypher Genomics, Inc., the ... Adam Simpson as president and chief ... comprehensive annotation and interpretation of individual human genomes ... "Cypher,s technology has the potential to play a ... accuracy, optimizing therapeutic approaches and reducing adverse drug ...
(Date:7/24/2014)... Diego, CA (PRWEB) July 24, 2014 ... the reporting of molecular diagnostic test results. It ... capabilities necessary for the validation and reporting of ... oncology. Molecular diagnostics is a rapidly growing area ... infectious disease, genetic predisposition, cancer, and companion diagnostics ...
Breaking Biology Technology:Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 2Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 3Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 3New DNA-barcode Patent Virtually Eliminates False Test Results and Sample Mix-up 2
... BRUNSWICK, N.J., Feb. 18 Senesco Technologies, Inc. ... financial results for the three months ended December 31, 2008. ... 2008 was $1,624,341, or $0.09 per share, compared with a ... three month period ended December 31, 2007. This increase ...
... a,biotechnology company focused on novel therapeutic and preventative,approaches ... of an EUR18M ($23M) Series B financing round ... operational and clinical level. Novartis Venture Fund,Fountain Healthcare ... all participated in the funding. , ...
... more light than heat. Engineers working in optical technologies ... with much greater speed than do electrical signals, says ... Bethlehem, Pa. If they are guided with sufficient precision ... can bring about applications in spectroscopy, sensing and medical ...
Cached Biology Technology:Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results 2Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results 3Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results 4Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results 5Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results 6Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results 7Opsona Therapeutics Closes EUR18M Funding 2Opsona Therapeutics Closes EUR18M Funding 3Opsona Therapeutics Closes EUR18M Funding 4Engineers tune a nanoscale grating structure to trap and release a variety of light waves 2Engineers tune a nanoscale grating structure to trap and release a variety of light waves 3
(Date:7/24/2014)... in German . ... they are a common sight on the roads of the ... the list of new vehicle registrations for the second time. ... where electric vehicles claim only a small portion of the ... Germany, only a mere 8000 are electric powered. The main ...
(Date:7/24/2014)... inside your gut that has gone undetected by scientists ... San Diego State University has found that more than ... described virus, named crAssphage, which infects one of the ... This phylum of bacteria is thought to be connected ... appears today in Nature Communications ., Robert A. ...
(Date:7/23/2014)... Protection Agency (EPA) today announced that environmental health ... Amherst School of Public Health and Health Sciences ... Achieve Results (STAR) grant to measure indoor air ... in subarctic North America to determine possible health ... culturally-relevant recommendations for mitigation. , Peltier, who will ...
Breaking Biology News(10 mins):Nano-supercapacitors for electric cars 2Nano-supercapacitors for electric cars 3Newly discovered gut virus lives in half the world's population 2Newly discovered gut virus lives in half the world's population 3Studying impacts of indoor air pollution on tribal communities 2Studying impacts of indoor air pollution on tribal communities 3
... the logic of inheritance in his monastery garden with no ... House. So why couldn,t Darwin have done it too? A ... influences and research focus gave him a viewpoint that prevented ... even in his own work. Darwin,s commitment to ...
... just off the east coast of Australia, picturesque North ... some of the inhabitants of the island,s creeks and ... territorial creatures, explains ecologist Robbie Wilson of the University ... one another, they size each other up in a ...
... HAVEN, FLFresh strawberries. Just the mention of this iconic ... of shortcake, fruity drinks and sweet desserts. Researchers interested ... that "sensory quality" of strawberries, a strong influence on ... of sweetness, aroma, texture, and appearance. The goals ...
Cached Biology News:Why didn't Darwin discover Mendel's laws? 2Crafty Australian crayfish cheat 2Analysis of fresh strawberries reveals consumer preferences 2
Glutamate Receptor 5/1a...
... [EP282Y] to Asparagine synthetase ( ... applications). Antigen: ... residues in the C-terminus of ... Entrez GeneID: 440 ...
Shh Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Anti-human C5/C5b, Clone 568, Monoclonal Antibody...
Biology Products: